DGAP-News 5150 0 Kommentare MeVis Medical Solutions AG: Existing trends continued - Seite 2

Depreciation and amortization came to EUR 677 k (down 25 % year on year, primarily due to lower scheduled write-downs on capitalized development costs), resulting in EBIT (earnings before interest and taxes) of EUR 3,610 k (up a significant 78 % on the previous year's figure of EUR 2,033 k) for the reporting period and a corresponding EBIT margin of 37 % (prev. year: 26 %).

The financial result improved significantly year on year, from EUR -979 k to EUR 1,095 k. Effects from the development of the US dollar exchange rate, combined with a high share of liquidity in US dollars, were largely responsible for this.

The tax result stood at EUR -1,150 k. After-tax earnings consequently fell by EUR 540 k to EUR 3,555 k, which is equivalent to undiluted earnings per share of EUR 1.95 (prev. year: EUR 2.25).

The interim report for Q3 2017 will be published August 22, 2017. The company's financial reports are available for download on the following website:

http://www.mevis.de/en/investor-relations/financial-reports/

18.05.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:	English
Company:	MeVis Medical Solutions AG
	Caroline-Herschel-Str. 1
	28359 Bremen
	Germany
Phone:	+49 421 224 95 0
Fax:	+49 421 224 95 999
E-mail:	ir@mevis.de
Internet:	http://www.mevis.de
ISIN:	DE000A0LBFE4
WKN:	A0LBFE
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange